17 June 2016
Eurofins Scientific (EUFI.PA), a world leader in bioanalytical testing supporting the entire food production chain, announces the acquisition of Bureau de Wit B.V. (“Bureau de Wit”), one of the main laboratory service providers focused on food and water safety testing for the food production, hotel and catering sectors in The Netherlands.
Bureau de Wit operates a strategically-located laboratory in Almere, and employs 64 staff, generating annual revenues in excess of EUR 5m. The company provides food and water safety and hygiene testing, with a strong reputation in the hotel and catering sectors due to its innovative, client-friendly tools and state-of-the-art client portals. Bureau de Wit’s existing competencies are entirely complementary to Eurofins’ portfolio of services, which should result in substantial cross-selling opportunities. Furthermore, its laboratory’s central location provides a perfect fit with Eurofins’ existing geographic footprint in the country.
This acquisition further reinforces Eurofins’ leadership in the Dutch food testing market and broadens its client base. In return, Bureau de Wit will benefit from Eurofins’ industry-leading laboratory network, including access to the Group’s comprehensive analytical portfolio, as well as logistical infrastructure. The existing Management of Bureau de Wit remains in place and will continue to work on the growth of the Bureau de Wit business, now as part of the successful Eurofins organisation.
Comment from Dr. Gilles Martin, Eurofins CEO: "This transaction further consolidates our leading footprint to support the food industry in The Netherlands. We look forward to giving Bureau de Wit’s clients access to the capabilities of the Eurofins network to support them in strengthening their quality and safety programs.”
For more information, please visit www.eurofins.com or contact:
Eurofins Investor Relations
Phone: +32-2-766 1620
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific believes it is the world leader in food, environment and pharmaceutical products testing, as well as one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forwardlooking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.